Source: https://www.casewatch.net/doj/humble/indictment.shtml
Timestamp: 2019-04-23 14:54:08+00:00

Document:
In 2010, Linda C. Bunch, M.D., Dallas Humble, D.C., and businessman Paul Temple were charged with illegally conspiring to sell human growth hormone (hGH) to patients at their Northeast LA Anti-Aging and Wellness Center in Monroe, Louisiana. Bunch was trained in internal medicine but focused her practice on "anti-aging and wellness care" that included chelation therapy. Humble is a prominent chiropractic practice-management consultant who now does business as the Make It Happen Network. Temple is a businessman who operates Temple Systems, Inc.
Growth hormone can be legally prescribed for growth deficiencies, but importing or marketing it for other purposes is a federal crime. The indictment (shown below) states that Temple arranged for importation from China and the others prescribed it to patients for "anti-aging" purposes. In 2011, Bunch pleaded guilty to conspiracy to import and distribute hGH and Temple pleaded guilty to facilitation and receipt of hGH. Bunch also entered a consent order with the Louisiana State Board of Medical Examiners that called for a $3,000 assessment, a ban on off-label prescribing of drugs, sand three years of monitored probation if and when she resumes practice. She is also required to take courses in ethics. In 2012, Humble pleaded guilty to conspiring to smuggle and sell hormones and a count of aiding and abetting in their illegal distribution. Temple was sentenced probation for 5 years. Bunch and Humble were each sentenced to 27 months in prison plus forfeiture of $200,000. Bunch then tried to change her plea, but the District Court judge denied the request and also refused to delay imprisonment while she appeals further.
A. The Northeast Louisiana Anti-Aging and Wellness Center ("NLAWC" or " the Center") provided anti-aging services to patients. The Center was located at 2501 Ferrand Street, Monroe, Louisiana, and 3602 Cypress Street, West Monroe, Louisiana.
B. The Defendant, LINDA C. BUNCH, practiced as a physician at the NLAWC.
C. The Defendant, DALLAS D. HUMBLE, a chiropractor by training, owned and managed the NLAWC.
D. The Defendant, PAUL N. TEMPLE, d/b/a Temple Systems, Inc., operated his computer business out of offices located at 3602 Cypress Street, Suite A, West Monroe, Louisiana, and is not, nor has he ever been a licensed medical doctor.
A. The United States Food and Drug Administration ("FDA") was the agency of the United States responsible for enforcing the provisions of the federal Food, Drug, and Cosmetic Act (the "FDCA"), 21 U.S.C. § 301 et. seq. The FDA's responsibilities included regulating the manufacture, labeling and distribution of prescription drugs shipped or received in interstate commerce.
B. The FDCA prohibited the knowing distribution of, or possession with intent to distribute, human growth hormone ("hGH") for any use in humans other than the treatment of a disease or other recognized medical condition that had been authorized by the Secretary of the United States Department of Health and Human Services ("HHS") and that was pursuant to the order of a physician. 21 U.S.C § 333(e).
C. The term hGH means somatrem, somatropin, or analogue of either somatrem Of somatropin. 21 U.S.C. § 333(e) (4). Somatrem was an analog of somatropin. Somatropin was a synthetic or naturally occurring growth hormone from the human pituitary gland.
adult growth hormone deficiency characterized as: (a) Adult-onset growth hormone deficiency; and (b) Childhood onset growth hormone deficiency.
adults with short bowel syndrome.
The FDA did not approve the use of hGH imported from China for any use.
F. Genescience Pharmaceuticals Company, LTD (hereinafter "GenSci") operated out of Changchun, in the People's Republic of China and supplied hGH to the Defendants directly and indirectly.
Knowingly possessing with an intent to distribute, distributing and dispensing, and causing to be distributed and dispensed, human growth hormone ("hGH"): (1) for a purpose other than the treatment of a disease or other recognized medical condition, the use of which had been authorized by the Secretary of Health and Human Services, in that neither the Secretary of Health and Human Services pursuant to Title 21, United States Code, Section 355 (prohibiting the introduction into interstate commerce of a new drug without proper application and approval) and (2) pursuant to the order of a physician, in violation of Title 21, United States Code, Sections 333(e).
The primary object of the conspiracy was to distribute hGH for sale for anti­ aging and other unapproved purposes.
The Defendants provided money to co-conspirators for the purchase of hGH from China-based and U.S.-based manufacturers.
The hGH manufacturers caused vials of hGH to be delivered from China and elsewhere to the NLAWC in Monroe, Louisiana.
The Defendants then caused the vials containing hGH delivered from China and elsewhere to be provided to NLA WC patients and NLAWC employees in the Western District of Louisiana and to customers elsewhere.
The Defendants tracked the distribution of hGH to NLA WC patients, NLA WC employees and others in part through the use of hGH Inventory Lists.
On or about October 20, 2006, PAUL N. TEMPLE wire transferred $1,780.00 to the Bank of China for the purchase of hGH from GenSci.
The allegations of Counts 2-22 are re-alleged and incorporated byreference as though fully set forth herein as separate overt acts.
All in violation of Title 18, United States Code, Section 371 l18 U.S.c. § 371].
A. The allegations of Count 1 are re-alleged and incorporated by reference as though fully set forth herein.
all in violation of Title 21, United States Code Section 333(e) and Title 18, United States Code Section 2. 21 u.s.c. § 333(e) and 18 u.s.c. § 2.
A. The allegations of Counts 1 through 20 are re-alleged and incorporated by reference as though fully set forth herein.
B. Between on or about July 1, 2005 and July 12, 2005, the exact dates being uncertain, in the Western District of Louisiana and elsewhere, the Defendants, LINDA C. BUNCH and DALLAS D. HUMBLE, as aided and abetted by others known and unknown to the grand jury, did knowingly and fraudulently import and bring into the United States merchandise, and received, concealed, bought, and facilitated the transportation, concealment and sale of merchandise after importation, knowing the same to have been imported or brought into the United States contrary to law, that is the Defendants, LINDA C. BUNCH and DALLAS D. HUMBLE, then knowing that said merchandise, non FDA approved hGH from China, had been imported and brought into the United States contrary to law, and did aid and abet the same, in violation of Title 21, United States Code, Sections 331(a), (d), 352(f) and 355, all in violation of Title 18, United States Code Section 545 and Title 18, United States Code Section 2. 18 U.S.C. § 545 and 18 U.S.C. § 2.
A. The allegations of Counts 1 through 21 are re-alleged and incorporated by reference as though fully set forth herein.
B. On or about November 3, 2005, the exact dates being uncertain, in the Western District of Louisiana and elsewhere, the Defendant, PAUL N. TEMPLE, as aided and abetted by others, did knowingly and fraudulently import and bring into theUnited States merchandize, and received, concealed, bought, and in any manner facilitated the transportation, concealment and sale of merchandise after importation, knowing the same to have been imported or brought into the United States contrary to law, that is the Defendant, PAUL N. TEMPLE, then knowing that said merchandise, non FDA approved hGH from China, had been imported and brought into the United States contrary to law, in violation of Title Zl, United States Code, Sections 331(a), (d), 352(f), and 355, all in violation of Title 18, United States Code Section 545 and Title 18, United States Code Section 2. 18 U.S.c. § 545 and 18 U.s.C. § 2.
A. The allegations contained in Counts 1-22 of this Indictment are hereby re-alleged and incorporated by reference for the purpose of alleging forfeitures pursuant to Title 21, United States Code, Sections 333(e)(3) and 853.
1. MONEY JUDGMENT: A sum of money equal to at least $406,648.75 in United States currency, representing the amount of proceeds obtained as aresult of the offenses, 21 U.S.C. § 333(e), for which the Defendants, LINDA C. BUNCH, DALLAS D. HUMBLE, and PAUL N. TEMPLE, are jointly and severally liable.
2. REAL PROPERTY: Real property located at 3602 Cypress Street, WestMonroe, Louisiana.
3. OTHER PROPERTY: LINDA C. BUNCH's license to practice medicine inthe State of Louisiana.
D. By virtue of the commission, by the Defendants of one or more of the felony offenses charged in Counts One through Twenty-Three of this Indictment, any and all interest the Defendants' have in the above-described property is vested in the United States and hereby forfeited to the United States pursuant to Title 21, United States Code, Sections 853(a)(1) and (a)(2).
the United States of America shall be entitled to forfeiture of substitute property pursuant to Title 21, United States Code, Section 853(p), as incorporated by Title 218, United States Code, Section 333(e)(3). All in accordance with Title 21, United States Code, Section 853 and Rule 32.2(a), Federal Rules of Criminal Procedure.
This page was revised on September 24, 2013.

References: § 301
 § 333
 § 333
 § 371
 § 333
 § 2
 § 545
 § 2
 § 545
 § 2
 § 333